ACW
ACTINOGEN MEDICAL LIMITED
$0.0440
▼ -13.73%
Market cap
$170M
Turnover
$576,717
Last price
$0.0440
Day change
-13.73%
Announcements
13
Range, past year
Open 0.031 · Low 0.019 · Now 0.044 · High 0.072
Open ACW in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
ACW momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
43/100
Wyckoff phase
Downtrend1d
Trend stage
Breakdown
1 Day
-13.7%
1 Week
-18.5%
1 Month
-26.7%
1 Year
+37.5%
RSI
33
Avg daily range
8.4%
ACTINOGEN MEDICAL LIMITED scores 43 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 1 trading day. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -30.2%
- High volatility (ATR 8.4%)
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsACW announcements
Recent price-sensitive releases.
- 2026-09-23 Underwriting of unlisted options completed Issued Capital - Other
- 2026-09-23 ACW Alzheimers pivotal trial completes last patient visit Progress Report
- 2026-09-04 Response to ASX Price Query Response to ASX Query
- 2026-09-01 ACW unlisted options fully underwritten Issued Capital - Other | Progress Report
- 2026-08-27 ACW FY2026 results and outlook Preliminary Final Report
- 2026-08-27 ACW Appendix 4E and 2026 annual report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-30 June 2026 Quarterly activity report & Appendix 4C Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
More Health Care stocks
Most traded in the same sector.